Clinical efficacy of icotinib in lung cancer patients with different EGFR mutation status: a meta-analysis

Icotinib is a novel and the third listed epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), which exerts a good anti-tumor efficacy on non-small cell lung cancer (NSCLC). The efficacy of EGFR-TKIs has been shown to be associated with the EGFR mutation status, especially exon 19...

Descripción completa

Detalles Bibliográficos
Autores principales: Qu, Jian, Wang, Ya-Nan, Xu, Ping, Xiang, Da-Xiong, Yang, Rui, Wei, Wei, Qu, Qiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5464926/
https://www.ncbi.nlm.nih.gov/pubmed/28430623
http://dx.doi.org/10.18632/oncotarget.15475

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5464926/
https://www.ncbi.nlm.nih.gov/pubmed/28430623
http://dx.doi.org/10.18632/oncotarget.15475

Ejemplares similares